Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 2/20 | 0.40 |
| ▸ | CYP4F2 | P78329 | 3/20 | 0.33 |
| ▸ | CYP4A11 | Q02928 | 3/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21804872 | 0.81 | PPARD (0.44) | PPARDTDP1MAPTMAPK1TSHR | |
| SCHEMBL21805185 | 0.79 | DGKA (0.46) | — | |
| SCHEMBL23923374 | 0.79 | HTR2C (0.39) | — | |
| SCHEMBL19220632 | 0.77 | SMN1; SMN2 (0.39) | TDP1TSHR | |
| SCHEMBL21805170 | 0.77 | CASP2 (0.43) | MAPTMEN1KMT2A | |
| SCHEMBL23923270 | 0.77 | CASP2 (0.43) | MAPTMEN1KMT2A | |
| SCHEMBL12410134 | 0.76 | TSHR (0.38) | PPARDMAPTMAPK1TSHRMEN1 | |
| SCHEMBL21919804 | 0.76 | L3MBTL1 (0.45) | MAPTMAPK1 | |
| SCHEMBL28086861 | 0.76 | TDP1 (0.42) | CYP4F2CYP4A11TDP1MEN1GAA | |
| SCHEMBL28086859 | 0.76 | TDP1 (0.42) | CYP4F2CYP4A11TDP1MEN1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113166087-B | Screening agent and use thereof | 恩多塞特公司 | 2024-05-10 | — | — | CN | disclosed |
| US-20210323985-A1 | SHIELDING AGENTS AND THEIR USE | ENDOCYTE INC (US) | 2021-10-21 | — | — | US | disclosed |
| EP-3853213-A1 | SHIELDING AGENTS AND THEIR USE | Endocyte, Inc. (US) | 2021-07-28 | — | — | EP | disclosed |
| CN-113166087-A | Shielding agent and application thereof | 恩多塞特公司 | 2021-07-23 | — | — | CN | disclosed |
| WO-2020061293-A1 | SHIELDING AGENTS AND THEIR USE | ENDOCYTE, INC. (US) | 2020-03-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210323985-A1 | SHIELDING AGENTS AND THEIR USE | PSMA6, PSMA2, PSMA1 | PPARD 3169/4885CYP4F2 4651/4885CYP4A11 4879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.